Scientific Publications Citizens of Science

In our quest to invent life-transforming medicines for people with serious diseases, we encourage our colleagues to publish their research in leading scientific journals.

The links on this page are not affiliated with Regeneron Pharmaceuticals, Inc. Links to sites outside of Regeneron are provided as a resource to the viewer. Regeneron accepts no responsibility for the content of linked sites.

Featured Publications
  • Early-Stage Research
  • Clinical Research
Cardiovascular & Renal
Pharmacokinetics and pharmacodynamics of pozelimab alone or in combination with cemdisiran in non-human primates

Published in PLoS One. 2022 Jun 16;17(6):e0269749. doi: 10.1371/journal.pone.0269749. eCollection 2022.

General Medicine
Speed and need: twin development challenges in rapid response for a SARS-CoV-2 antibody cocktail

Published in Curr Opin Biotechnol. 2022 Mar 15;76:102715. doi: 10.1016/j.copbio.2022.102715. Online ahead of print.

Immunology & Inflamation
A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma

Published in Nat Cancer. 2022 Jun 6. doi: 10.1038/s43018-022-00391-0. Epub ahead of print.

Rare Diseases
ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1

Published in J Clin Invest. 2022 May 5:e153792. doi: 10.1172/JCI153792

Technology
Activity-Based Protein Profiling Probe for the Detection of Enzymes Catalyzing Polysorbate Degradation

Published in Anal Chem. 2022 Jun 9. doi: 10.1021/acs.analchem.2c00059. Online ahead of print.

Ultrasensitive disulfide scrambling analysis of mAbs by LC-MS with post-column reduction and glycine signal enhancement

Published in Anal Biochem. 2022 Jun 7:114773. doi: 10.1016/j.ab.2022.114773. Online ahead of print.

General Medicine
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Published in Circulation. 2022 Jun 30:101161CIRCULATIONAHA121057807. doi: 10.1161/CIRCULATIONAHA.121.057807. Online ahead of print.

Hematology
Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial

Published in Lancet Haematol. 2022;S2352-3026(22)00072-2. doi:10.1016/S2352-3026(22)00072-2

Immunology & Inflamation
Real-World Effectiveness of Dupilumab in Atopic Dermatitis Patients: Analysis of an Electronic Medical Records Dataset

Published in Dermatol Ther (Heidelb). 2022 May 11. doi: 10.1007/s13555-022-00731-z. Online ahead of print.

Impact of dupilumab on SNOT-22 sleep and function scores in CRSwNP

Published in J Allergy Clin Immunol Pract. 2022 May 23:S2213-2198(22)00501-3. doi: 10.1016/j.jaip.2022.05.013. Online ahead of print.

Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis

Published in J Allergy Clin Immunol Pract. 2022 May 27:S2213-2198(22)00507-4. doi: 10.1016/j.jaip.2022.05.019. Online ahead of print.

Oncology
Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression

Published in Ther Adv Med Oncol. 2022 Jun 16;14:17588359221105024. doi: 10.1177/17588359221105024. eCollection 2022.

Ophthalmology
Functional outcomes of sustained improvement on Diabetic Retinopathy Severity Scale with intravitreal aflibercept in the VISTA and VIVID trials

Published in Eye (Lond). 2022 Apr 19. doi: 10.1038/s41433-022-02058-7. Online ahead of print.

Back
to top